Skip to Main content Skip to Navigation
Journal articles

(188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside.

Nicolas Lepareur 1, * Valérie Ardisson 2 Nicolas Noiret 3 Etienne Garin 2
* Corresponding author
1 Microenvironnement et remodelage
Foie, métabolismes et cancer, UEB - Université européenne de Bretagne - European University of Brittany, ISCR - Institut des Sciences Chimiques de Rennes
2 Microenvironnement et remodelage
Foie, métabolismes et cancer, UEB - Université européenne de Bretagne - European University of Brittany
Abstract : Hepatocellular carcinoma (HCC) is the 5th most common tumour worldwide and has a dark prognosis. For nonoperable cases, metabolic radiotherapy with Lipiodol labelled with β-emitters is a promising therapeutic option. The Comprehensive Cancer Centre Eugène Marquis and the National Graduate School of Chemistry of Rennes (ENSCR) have jointly developed a stable and efficient labelling of Lipiodol with rhenium-188 (E(βmax) = 2.1 MeV) for the treatment of HCC. The major "milestones" of this development, from the first syntheses to the recent first injection in man, are described.
Complete list of metadatas

Cited literature [45 references]  Display  Hide  Download

https://hal.archives-ouvertes.fr/hal-00866975
Contributor : Morgane Le Corre <>
Submitted on : Friday, September 27, 2013 - 3:03:53 PM
Last modification on : Thursday, February 11, 2021 - 9:12:19 AM
Long-term archiving on: : Saturday, December 28, 2013 - 4:30:41 AM

File

278306m.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Nicolas Lepareur, Valérie Ardisson, Nicolas Noiret, Etienne Garin. (188)Re-SSS/Lipiodol: Development of a Potential Treatment for HCC from Bench to Bedside.. International Journal of Molecular Imaging, Hindawi Publishing Corporation, 2012, 2012, 278306 (9 p.). ⟨10.1155/2012/278306⟩. ⟨hal-00866975⟩

Share

Metrics

Record views

623

Files downloads

530